• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK 4 Star

Last Price$55.51Day Change (%)0.69%
Open Price$55.23Day Change ($)0.38
Day Range55.00–55.8652-Week Range44.62–61.33

As of Thu 10/23/2014 07:45 AM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck Announces Pricing of Tender Offers for Eight Series of Notes

    Merck Announces Pricing of Tender Offers for Eight Series of Notes

  2. Merck Announces Tender Offers for Eight Series of Notes

    Merck Announces Tender Offers for Eight Series of Notes

  3. Merck Announces Proposed Public Debt Offering

    Merck Announces Proposed Public Debt Offering

  4. Sigma-Aldrich (NASDAQ - SIAL) Reports Q3 2014 Results With Sales Of $690 Million And Adjusted Diluted EPS Of $1.06. Declares $0.23 Per Share Quarterly Dividend.

    Sigma-Aldrich (NASDAQ - SIAL) Reports Q3 2014 Results With Sales Of $690 Million And Adjusted Diluted EPS Of $1.06. Declares $0.23 Per Share Quarterly Dividend.

  5. SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit In Connection With The Sale Of Sigma-Aldrich Corporation

    SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit In Connection With The Sale Of Sigma-Aldrich Corporation

  6. Schawk! BLUE Users Conference Draws Industry Leaders

    Schawk! BLUE Users Conference Draws Industry Leaders

  7. UPDATE: PetMed's results hurt by shortened flea and tick season -- seriously?

    UPDATE: PetMed's results hurt by shortened flea and tick season -- seriously?

  8. Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014

    Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014

  9. Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative

    Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative

  10. Merck & Co. Executive Pamela Demain Elected President of Licensing Executives Society (U.S.A. and Canada)

    Merck & Co. Executive Pamela Demain Elected President of Licensing Executives Society (U.S.A. and Canada)

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.